Aarti Drugs Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020
October 23, 2020 at 06:48 am EDT
Share
Aarti Drugs Limited announced earnings results for the second quarter ended September 30, 2020. For the second quarter, the company announced total revenue was INR 5,784 million compared to INR 4,776.9 million a year ago. Net income was INR 752.655 million compared to INR 323.1 million a year ago. Basic earnings per share from continuing operations was INR 32.3 compared to INR 13.87 a year ago. For the half year, total revenue was INR 11,243.3 million compared to INR 8,831.9 million a year ago. Net income was INR 1,607.154 million compared to INR 547.6 million a year ago. Basic earnings per share from continuing operations was INR 68.98 compared to INR 23.41 a year ago.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.